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AOX inhibitorsIn the present paper we have investigated the effect of mutagenesis of a number of highly conserved residues
(R159, D163, L177 and L267) which we have recently shown to line the hydrophobic inhibitor/substrate
cavity in the alternative oxidases (AOXs). Measurements of respiratory activity in rSgAOX expressed in
Escherichia coli FN102 membranes indicate that all mutants result in a decrease in maximum activity of AOX
and in some cases (D163 and L177) a decrease in the apparent Km (O2). Of particular importancewas the ﬁnding
thatwhen the L177 and L267 residues, which appear to cause a bottleneck in the hydrophobic cavity, aremutated
to alanine the sensitivity to AOX antagonists is reduced.When non-AOX anti-malarial inhibitorswere also tested
against these mutants widening the bottleneck through removal of isobutyl side chain allowed access of these
bulkier inhibitors to the active-site and resulted in inhibition. Results are discussed in terms of how these muta-
tions have altered the way in which the AOX's catalytic cycle is controlled and since maximum activity is de-
creased we predict that such mutations result in an increase in the steady state level of at least one O2-derived
AOX intermediate. Suchmutations should therefore prove to be useful in future stopped-ﬂow and electron para-
magnetic resonance experiments in attempts to understand the catalytic cycle of the alternative oxidase which
may prove to be important in future rational drug design to treat diseases such as trypanosomiasis. Furthermore
since single amino acid mutations in inhibitor/substrate pockets have been found to be the cause of multi-drug
resistant strains ofmalaria, the decrease in sensitivity tomainAOXantagonists observed in the L-mutants studied
in this report suggests that an emergence of drug resistance to trypanosomiasis may also be possible. Therefore
we suggest that the design of future AOX inhibitors should have structures that are less reliant on the orientation
by the two-leucine residues. This article is part of a Special Issue entitled: 18th EuropeanBioenergetic Conference.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
The alternative oxidase is a ubiquinol oxidoreductase that catalyses
the four electron reduction of oxygen to water. It is now generally rec-
ognized that the distribution of the alternative oxidase is substantially
wider than previously thought [1]. It is ubiquitous amongst plants,
and also found in some agrochemically important fungi (such as
Septoria tritici — a wheat pathogen) and protists [1,2]. Importantly it is
also widespread amongst human parasites such as Trypanosoma brucei
(the causative agent of African Sleeping Sickness) [3,4], intestinaloctyl gallate; SHAM, salicylic
ne; AOX, alternative oxidase;
xidase
opean Bioenergetic Conference.
44 1273 678433.parasites such as Cryptosporidium parvum [5,6] and Blastocystis hominis
[7] and opportunistic human pathogens such as Candida albicans [8]. It
should be noted that immunocompromised individuals are particularly
susceptible to these opportunistic human diseases, and new drugs
that are well tolerated and have clearly deﬁned biochemical targets
are therefore urgently required [9]. Since the alternative oxidase is
absent from the human host and is essential for the life-cycle of the
trypanosomal parasite within the blood-stream [4] there is growing
support for this protein to be considered as a viable target for the treat-
ment of trypanosomiasis and indeed other diseases in which the alter-
native oxidase plays a key metabolic role [10–12]. Indeed treatment of
mice infected with trypanosomes by the antibiotic ascofuranone at
sub-nM concentrations rapidly clears the parasite from the blood-
stream without any adverse effects upon the animal [13]. Furthermore
the chemotherapeutic efﬁcacy of ascofuranone in vivo has also been
conﬁrmed [14].
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[15], generally accepted structural models predicted that the AOX is
an integral interfacial monotopic protein that interacts with a single
leaﬂet of the lipid bilayer and contains a non-haem diiron carboxylate
active site [1,16,17]. Such models are supported by extensive site-
directed mutagenesis and spectroscopic studies [18–25]. Non-haem
diiron-containing enzymes are a ubiquitous and diverse super-family
of metalloenzymes [26]. They can be divided into different sub-
families with a wide range of distinct catalytic functions such as
oxidation, hydroxylation or desaturation and act on a wide variety of
substrates. Despite their different activities, many of the enzymes in
this family share very common structural elements. These include a
common fold involving a four-helix bundle, a bridging carboxylate
group in the diiron site and the presence of common ligands [26]. In
addition they all possess a common catalytic function namely the
activation of molecular oxygen [9,10]. The alternative oxidases are the
newest and currently largest sub-class of the diiron protein family.
The acquisition of a high-resolution structure of the alternative oxidase
is amajor breakthrough since it not only represents the ﬁrst structure of
any AOX or a membrane-bound diiron protein but also is the last of the
mitochondrial respiratory quinol oxidases to be solved [15]. Crystal
structures conﬁrmed that theAOX is a homo-dimerwith eachmonomer
being comprised of 6 long α-helices, 4 of which form a 4 helix bundle
which acts as a scaffold to bind the two iron atoms (connected by
hydroxo bridge). The iron atoms within the active-site under oxidised
conditions are co-ordinated by 4 glutamate residues but no histidine
residues which is an unusual co-ordination for a diiron protein
[15,26]. Of particular signiﬁcance was the ﬁnding that the redox-active
tyrosine (Y275 — Sauromatum guttatum numbering) is within 4 Å of
the active-site consistentwith its proposed role in the oxygen reduction
cycle [1,27]. In addition to thewild-type enzyme, high-resolution struc-
tures of the active site of the protein in the presence of ascofuranone-
derivatives, AF2779OH and colletochlorin B have also been described
[15]. Such structures revealed the presence of a hydrophobic channel
that connects the diiron centre with the interior of the lipid bilayer in
a manner analogous to the channels observed in the yeast NADH dehy-
drogenase (Ndi1) [28], prostaglandin H2 synthase [29] and Complex I
[30]. All of the inhibitors appeared to enter the AOX active-site via this
hydrophobic channel and docking studies suggest that it is also the
channel through which ubiquinol enters and binds to the active-site
[15,27].
In an attempt to further probe the nature of the substrate-binding
site, we have generated a number of mutants within the diiron centre
and at the entrance to the hydrophobic pocket in rSgAOX. Mutagenesis
of highly conserved residues (R159, D163, L177 and L267) to alanine, all
of which line the hydrophobic inhibitor/substrate cavity in AOX, result-
ed in a decrease in maximum activity of AOX and in the case of D163
and L177 a decrease in the apparent Km (O2). Of particular interest
was the ﬁnding that the mutation of both L177 and L267 severely re-
duced the sensitivity of rSgAOX to AOX antagonists colletochlorin B
and ascofuranone whilst increasing the sensitivity to bulky quinolone
antimalarials. Such results are consistent with these residues acting as
a gate to orientate substrates and inhibitors into the correct conforma-
tion to enter the active-site.
2. Materials and methods
2.1. Strains
The Escherichia coli strains DH5α and JM110 were used for ampliﬁ-
cation of plasmids and FN102 [31] for expression of rSgAOX.
2.2. Site-directed mutagenesis and plasmid construction
The S. guttatum AOX lacking the mitochondrial targeting signal se-
quence was used for expression in E. coli. Prediction of the cleavagesite was performed using MitoProt (http://ihg2.helmholtz-muenchen.
de/ihg/mitoprot.html) [32]. In order to remove the leader sequence
and facilitate cloning, a recognition site for NdeI was introduced at the
cleavage site of the AOX. Firstly the orientation of the AOX cDNA in
pAOSG81 [33]was reversed by digestionwith EcoRI followed by ligation
of the resulting fragments to give pAOSG/R. This plasmid, together with
primers 5′-GTTCTCGCCCCCCCGCCATATGAGCACGCTGTCAGC-3′ and 5′-
GCTGACAGCGTGCTCATATGGCGGGGGGGCGAGAAC-3′ was used to in-
corporate the NdeI site (alteration underlined) and was performed
using the Quick-Change mutagenesis kit (Stratagene) according to the
manufacturer's instructions. The mature AOX sequence was removed
on an NdeI–BamHI fragment and ligated to NdeI–BamHI digested
pET15b (Novagen) to produce the expression construct pET.SgAOX.
The recognition sequence of the NcoI site present in the pET vector
was removed, by altering to GCATGG, in order to facilitate the construc-
tion of AOX mutants.
Construction of pET.T179A was carried out by removal of an
NcoI–BamHI fragment from pREP1-T179A [34] and ligation to NcoI–
BamHI digested pET.SgAOX.
Mutagenesis of AOX was performed using the Quick Change muta-
genesis kit (Stratagene) according to the manufacturer's instructions.
The list in Section 2.3 describes the oligonucleotides used for each mu-
tation, with altered codons in bold and underlined. Mutagenesis was
carried out with pSLM-AOR [21] yielding pQC.L177A, pQC.L267A,
pQC.R159A and pQC.D163A respectively.
pQC.L177A and pQC.L267Awere used initially to construct plasmids
for expression in Schizosaccharomyces pombe. Each full-length mutant
AOX was excised on a BspHI–BamHI fragment and ligated to the yeast
expression vector pREP1/N (a modiﬁed version of pREP1 [35] in which
the NdeI site was replaced with NcoI), which had been digested with
NcoI and BamHI, yielding pREP1-L177A and pREP1-L267A. For E. coli ex-
pression, the mutant AOX fragment was removed from the yeast vector
on an NcoI–BamHI fragment and ligated to NcoI–BamHI digested
pET.SgAOX to produce pET.L177A and pET.L267A, respectively. Con-
struction of pET.R159A and pET.D163A was carried out by removal of
the mutant AOX on an NcoI–BamHI fragment from pQC.R159A and
pQC.D163A. The mutant AOX fragments were ligated to NcoI–BamHI
digested pET.SgAOX to produce pET.R159A and pET.D163A, respectively.
2.3. Primers
Oligonucleotides used for site-directed mutagenesis to produce
mutated forms of S. guttatum AOX. Altered codons are in bold and
underlined.Mutation Primer sequenceL177A L177A/F CGG GCG ATG ATG GCG GAG ACG GTG GC
L177A/R GC CAC CGT CTC CGC CAT CAT CGC CCGL267A L267A/F GTT GTG GGC TAC GCG GAG GAG GAG GCC
L267A/F GGC CTC CTC CTC CGC GTA GCC CAC AACR159A R159A/F C GTC AAG GCC CTC GCG TGG CCC ACC GAC
R159A/R GTC GGT GGG CCA CGC GAG GGC CTT GAC GD163A D163A/F CGG TGG CCC ACC GCG ATC TTC TTC CAG C
D163A/R G CTG GAA GAA GAT CGC GGT GGG CCA CCG2.4. Expression of rSgAOX in E. coli membranes
E. coli (FN102) cells were transformed with the pET.SgAOX con-
struct, and grown overnight on selective Luria agar supplemented
with 100 μg/ml amino-levulinic acid (ALA), 50 μg/ml kanamycin and
100 μg/ml ampicillin. A single colony was used to streak a fresh agar
plate with the same supplements, and was incubated for 12 h at 37 °C.
A scrape of cells from the streak platewas used to inoculate 50ml start-
er culture (Luria broth, 100 μg/ml ALA, 50 μg/ml kanamycin, 50 μg/ml
ampicillin). The starter culture was grown at 37 °C with shaking for
~4 h, followed by centrifugation at 8000 g for 5 min and resuspension
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from themedia. The centrifugation and resuspension stepwas repeated,
and the resultant cell suspension was used to inoculate 5 l of K-broth
(50 g tryptone–peptone, 25 g yeast extract, 25 g casamino acid, 52 g
dipotassium hydrogen orthophosphate, 15 g potassium dihydrogen or-
thophosphate, 3.7 g trisodium citrate, 12.5 g ammonium sulphate, 0.25
g magnesium sulphate, 0.125 g iron sulphate, 0.125 g iron chloride, 100
g glucose and 0.5 g carbenicillin). The cultures were incubated with
shaking at 30 °C until the OD600= 0.1, at which point the cells were in-
ducedwith 25 μM IPTG. After induction, the cultures were incubated for
a further 14 h at 30 °C with shaking.
Following the 14-hour growth period, cells were harvested by cen-
trifugation at 8000 g (10 min) and cell pellets were resuspended in
50mMTris–HCl, 10mM pyruvate, pH 7.5. After the pellets were pooled
and homogenised, a protease inhibitor cocktail (Roche “Complete”)was
added, before lysis using a French Press (10 k psi, two passes). After
lysis, cell debris was removed in a single 12,000 g centrifugation step
(15 min), and the supernatant was centrifuged for 1 h at 200,000 g.
The pellets containing membrane were then resuspended in a minimal
volume of 50 mM Tris–HCl, 10 mM pyruvate, pH 7.5 prior to snap
freezing, storage or experimentation.
2.5. Oxygen uptake
Respiratory activity was measured with a Clark-type electrode
(Rank Brothers, Cambridge, U.K.) using 0.1–0.5 mg E. colimembranes
suspended in 0.4 ml air-saturated reaction medium (250 μM at 25 °C)
containing 50 mM Tris–HCl (pH 7.5).
2.6. Oxygen afﬁnity
O2 levels were recorded continuously, in the presence of antimycin
A and KCN, until anaerobiosis occurred. The derivative with respect
to time of these O2 traces was calculated with Chart software
(ADInstruments) using a window of 16.5 s (11 data points), which
allowed expression of O2 uptake rates as a function of the correspond-
ing O2 levels. Estimations of AOX's afﬁnity for O2 from respiratory traces
are subject to potential pitfalls, as respiratory activity is not necessarily
controlled exclusively by AOX activity, but also by that of substrate
dehydrogenases [36]. We have shown previously, however, that AOX
exerts nearly 95% of total ﬂux control over inhibitor resistant NADH ox-
idation in isolated S. pombemitochondria [36] and the results presented
in Table S1 suggest that this is also the case with E. coli membrane
bound AOX. For instance wild-type and mutant NDH-2 activity consid-
erably exceeds themaximal AOX activity (Table S1). Hencewhen respi-
ration is limited by oxygen, this will therefore be the direct result of the
kinetic characteristics of AOX [34]. Table S1 also demonstrates that
none of the AOX inhibitors tested in this publication had any effect
upon either wild-type or mutated AOX NDH-2 activity.
2.7. Colletochlorin B synthesis
Colletochlorin B was synthesised using the technique described by
[37], with minor modiﬁcations to the ﬁnal product puriﬁcation. The
product was puriﬁed via ﬂash chromatography (petrol ether 40–80:
diethyl ether 10:1→ 4:1), followed by recrystallisation from chloro-
form to obtain the compound as white needles in 20% yield.
2.8. General molecular biology procedures
Oligonucleotides were obtained from MWG Biotech. Sequencing
was performed by Beckman Coulter Genomics. Other procedures were
as described by Sambrook et al. [38].
All chemicals were of biochemistry grade. The protease inhibitor
‘cocktail’ was purchased from Roche.3. Results
We previously ascertained the location of the ubiquinol-binding
site by soaking TAO crystals with speciﬁc AOX inhibitors such as
ascofuranone derivatives (AF27709OH) and colletochlorin B (CB) [15].
X-ray data indicated that the two inhibitors bind in a very similar man-
ner approximately 4–5Å from thediiron centre and CAVER visualisation
software [39] revealed that both are located within a hydrophobic cav-
ity which stretches from the diiron centre to the interior of the phos-
pholipid bilayer. We refer to this channel as the L-channel owing to
the presence of two leucine residues located at the centre of the chan-
nel. The L-cavity is located (Fig. 1A) between the membrane-binding
helicesα-1 and α-4 and is mostly lined by highly conserved hydropho-
bic and charged residues (V155, R159, R173, L177, V180, L267, E270,
A271 and S/T274 — note SgAOX numbering used throughout) some of
which we have previously shown to be essential for catalytic activity
[1,15,18]. An important aspect of the channel is that although it is
~18–20 Å long from the surface of the protein to the diiron centre at
the cavity entrance, which is framed by helices α1 and α4, it is approx-
imately 12 Å wide. It then narrows to a width of approximately 6.5 Å at
the location of L177 and L267 before widening at the entrance to the
active-site (Fig. 1B). We have previously built a ubiquinone-binding
model by superimposing a ubiquinolmolecule onto the bound structure
of the TAO–AF27709OH complex [15] and similar models have been
generated using the TAO–CB complex (Fig. 1C). Both models suggest
that ubiquinol is within ~4–5 Å of the diiron centre and the narrowness
of the L-channel suggests that the ubiquinol tail will be in an extended
conformation and will protrude from the cavity into the lipid bilayer
by approximately six to seven isoprenoid units.We suggest that the bot-
tleneck within the L-channel, although wide enough to accommodate
the passage of ubiquinol (OH\OH — 6 Å), serves as a gate to position
the substrate into the correct molecular orientation (Fig. 1C) to interact
with the diiron centre such that the C2\OH forms a hydrogen bond
with R173 and S/T274 [15].
In an attempt to further probe this gating role of the highly con-
served leucines within the L-channel, a number of mutant recombinant
proteins were generated. Since all of the above residues are fully
conserved in all species [1], mutant proteins were generated in the
rSgAOX in order to compare the effects of such mutations with a well-
documented mutation that affects both respiratory activity and the Km
for oxygen. In addition to the L177A and L267Amutants we also mutat-
ed R159 and D163 both of which are highly conserved across all species
and located within the L-channel (Fig. 1B). Docking studies reveal that
ubiquinol is able to bind with the aromatic head group occupying the
same space as that of either colletochlorin B or AF2779OH within the
active-site such that 1-OH interacts with R159 (see Fig. 1C and Ref.
[16]). D163, which is equally very highly conserved, has also been
previously suggested to be involved in ubiquinol-binding since in the
presence of an inhibitor such as colletochlorin B, R173 forms a new
hydrogen bond with D163, causing rotation in the position of R159
[1,15]. Given the assignment of R159 as a potential membrane binding
residue, this implies that binding of the substrate within the active site
causes a conformational change that would lower the effective binding
to the membrane.
Table 1 summarises NADH dependent respiratory activity on
membrane-bound SgAOX isolated fromhaem-A deﬁcient cells expressed
in E. coli strain FN102. Since this particular E. coli strain lacks glutamyl-
tRNA reductase [31], it has a limited capacity to synthesise respiratory
complexes bd and bo. Nevertheless both KCN and antimycin A were in-
cluded in the assaymedium to ensure thatwhatever limited respiratory
complexes were still present their potential activity did not complicate
respiratory measurements. Furthermore the lack of any effect of
piericidin A or rotenone on NADH activity (data not shown) suggested
that only NDH-2 was operative under these conditions and in agree-
mentwith our previous ﬁndings overall respiratory activity is not limit-
ed by substrate dehydrogenase but is fully controlled by AOX [36]. All of
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α5
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α2
α2
α3
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Fig. 1. Location of the ubiquinol-binding cavity in TAO. (A) A hydrophobic cavity (coloured
purple) predicted for eachmonomer by CAVER protein-analysis software [39]. Helices are
shown as grey cylinders and helicesα1 andα4 anchor the protein to the innermembrane.
Helices α2, α3, α5 and α6 act as a scaffold to bind the diiron centre. Brown spheres are
diiron (Fe–OH−–Fe) centre bridged by OH− (red sphere), green sticks represent residues
coordinating thediiron centre, and the yellow stick is the redox active Tyr275. (B) Location
of themutations (light pink sticks) examined in this study. (C) Location of ubiquinol bind-
ing predicted by the superposition of a ubiquinol molecule (cyan spheres) onto a bound
inhibitor generated using PDB ID: 3W54. Oxygen and nitrogen atoms are coloured
red and blue, respectively. Note the SgAOX numbering used throughout the ﬁgure.
Figures were generated using PyMOL.
Table 1
Effect of site-speciﬁc mutations on the activity of membrane bound rSgAOX expressed in
E. colimembranes.
Mutation Speciﬁc activity
(nmol O2 min−1 mg−1)
Activity
(%)
App Km (O2)
(μM)
rSgAOX 230 ± 56 100% 13.1 ± 0.3
T179A 66 ± 36 28% 6.1 ± 0.4
D163A 72 ± 12 31% 5.9 ± 0.4
R159A 56 ± 19 24% 10.8 ± 0.2
L177A 118 ± 32 51% 8.9 ± 0.6
L267A 94 ± 3 41% 16.5 ± 1.2
Activities were measured using an oxygen electrode in 400 μl-50 mM Tris–HCl, pH 7.4,
10 mM pyruvate, 4 μM antimycin A and 1.25 mM NADH as the substrate, and apparent
oxygen afﬁnities [Km (O2)] were determined as described in Materials and methods.
Data are averages ± S.E.M. of 2–5 separate membrane preparations. Percentage activity
refers to percent of activity remaining relative to wild-type rSgAOX.
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of the wild-type. In SgAOX expressed in E. coli the T179A mutant also
clearly had a major inhibitory impact upon respiratory activity compa-
rable to that observed in S. pombemitochondria [34]. The R159A (76% ofcontrol) and D163A (69%)mutations were equally as inhibitory where-
as L177 or L267 mutations only inhibited the respiratory rate by
approximately 50%. Addition of 10 mM pyruvate (data not shown) did
not affect the respiratory activity of any of the mutants indicating that
they are not regulated by α-keto acids, as is indeed the case for the
wild-type S. guttatum AOX [34]. Fig. S1 indicates that although AOX is
expressed in all mutants, total level of AOX expression is variable and
does not appear to be related to activity when compared with Table 1.
For instance, the L267Amutant appears to be expressed in similar quan-
tities to wild-type but signiﬁcantly more that the L177 mutant yet
overall activity of both mutants is approximately 50% of control. Such
results suggest that the mutation has a speciﬁc effect upon the activity
of AOX and not merely an effect on the level of protein within the cell.
Fig. 2 shows typical O2-dependencies of AOX activity. Fig. 2A indi-
cates a respiratory trace obtained by wild-type AOX with NADH as a
substrate and Fig. 2B is the derivative display. In the Eadie–Hofstee
plots derived from these results we have only extracted data in the
oxygen dependent region which as can be seen from Fig. 2C is linear.
Such results are in agreement with similar measurements in rSgAOX
expressed in S. pombe mitochondria [34] and strongly suggest that
both wild-type and mutant AOX proteins exhibit simple Michaelis–
Menten kinetics with respect to O2. Average O2 afﬁnities calculated
from 2 to 6 independent experiments are listed as apparent Km (O2)
values in Table 1. The apparent Km (O2) of wild-type rSgAOX and the
L267A mutant are approximately 14 μMwhich although slightly lower
are nevertheless comparable to values determined with rSgAOX
expressed in S. pombe [34] and importantly observed by others in
plant mitochondria [40] suggesting that the expression system used in
this study results in recombinant proteins that exhibit similar kinetic
properties to that observed with isolated organelles. Importantly, the
O2 afﬁnity of the T179A and D163A mutants is substantially higher
than that of the wild-type enzyme. Less pronounced effects upon the
apparent Km (O2) were also observed with the L177A and R159A mu-
tants (Table 1) but these are probably not statistically signiﬁcant
when compared to wild-type. In all cases where a mutation resulted
in an increase in oxygen afﬁnity no change in the reaction stoichiometry
of AOX could be detected (unpublished results) and remained consis-
tent with a complete 4-electron reduction of O2 to water.
In order to determine if any of these mutations have affected the in-
teraction of AOX with its substrate, the sensitivity to a number of AOX
antagonists were examined the inhibitory effects of which are
summarised in Table 2. As in Table 1 1.25 mM NADH, in the presence
of 4 μM antimycin A and 1 mM KCN, was used as the respiratory sub-
strate and membranes were pre-incubated with inhibitor for approxi-
mately 2 min prior to addition of substrate. As is apparent from
Table 1 both ascofuranone and colletochlorin B are far more potent in-
hibitors of SgAOX respiratory activity than conventional AOX inhibitors
such as SHAM or octyl gallate.When the same inhibitors were tested on
either the L177A or L267A mutant, however, IC50s for all inhibitors in-
creased substantially suggesting that such mutations conferred a high
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Fig. 2.O2 afﬁnities ofwild-type andmutant rSgAOXexpressed in E. colimembranes. (A)O2
consumption was recorded continuously acquiring 40 data per minute; (for clarity, even
distributions of only 50 data points are shown). (B) A typical derivative graph based
upon the data obtained from the O2 consumption measurements shown in A. Data were
modelled assuming Michaelis–Menten kinetics to calculate O2 afﬁnities; typical experi-
ments are shown, and averaged apparent Km (O2) values of 3–5 independent membrane
preparations are given in Table 1. (C) Eadie–Hofstee representation of the respective
data sets, ﬁtted with linear expressions, conﬁrming Michaelis–Menten behaviour with
respect to O2. Data at lowO2 (below 2.5 μM)were omitted as error in V/O2 tends to inﬁnity
when O2 approaches zero.
Table 2
Sensitivity of wild-type and mutant forms of rSgAOX expressed in E. colimembranes to
AOX antagonists.
Inhibitor wt
IC50 μM
L177A
IC50 μM
L267A
IC50 μM
Colletochlorin B 0.45 ± 0.1 31 ± 2 35 ± 8
Ascofuranone 1.12 ± 0.2 N500 N500
Octylgallate 1 ± 0.4 N500 N500
SHAM 45 ± 8 N.I. N.I.
SL-2-25 22 ± 10 4 ± 1 20 ± 5
PG75 5.3 ± 2 1.3 ± 0.01 0.48 ± 0.07
Oxygen consumption of wild-type and mutated forms of rSgAOX (approx. 1.25 mg/ml)
expressed in E. coli membranes was measured as indicated in Materials and methods
using 1.25 mM NADH as substrate. IC50 is the mid-point inhibition concentration and
the values are themean of 3 separatemeasurements. All data normalised by standardising
the IC50 per rate (used 60 nmol O2 min−1 mg−1) and then correlated to the NADH
rates given in Table 1 (51% — L177A, 41%— L267A). N.I. indicates that no inhibition was
observed even at concentrations N500 μM.
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bottleneck within the hydrophobic cavity was removed IC50s increased
at least N20-fold (and in the case of ascofuranoneN500-fold). In the case
of SHAM no inhibition of the respiratory rate could be detected even at
concentrations up to 500 μM. In an attempt to conﬁrm whether or not
changes in potency of the inhibitors were indeed a direct reﬂection of
a widening of the channel we tested the effect of bulkier anti-malarial
inhibitors, SL-2-25 and PG75 [41,42]. SL-2-25 and PG75 are diheteroaryl
quinolones which are potent anti-malarial inhibitors. What is immedi-
ately obvious from Table 2 is that, when the bottleneck is removed
by exchanging L177 and L267 for alanine, although the sensitivity to
SL-2-25 remains unchanged, the sensitivity to PG75 increases approxi-
mately 10-fold particularly with the L267A mutant.4. Discussion
AOX within the blood-stream form of T. brucei and in phytopatho-
genic fungi is increasingly considered to be a valid drug and fungicide
target as in all cases it appears essential for their continued life cycles
[1] and with respect to trypanosomiasis the parasite is absent from
the mammalian host [4]. Until recently little information on the nature
of the AOX active-site was available rendering rational drug design,
which targeted the AOX for the treatment of trypanosomiasis, difﬁcult.
Structural elucidation of the trypanosomal AOX, however, not only
conﬁrmed previous models that the enzyme is indeed a diiron protein
but also demonstrated that under oxidised conditions it contains an
unusual active-site geometry [15]. Importantly structural studies
also revealed the nature of the inhibitor-binding site for both an
ascofuranone derivative and colletochlorin B [15] is also revealed. In
each case (both equally inhibit at sub-nM concentrations) the aromatic
head is located close to the diiron active-site (within 4.3 Å of Fe2) and is
held in position through a hydrogen bond network involving Y275 and
E178 suggesting that the binding cavity for both is identical. We have
previously demonstrated using CAVER protein-analysis software [1]
(Fig. 1) that the diiron centre is connected to the bulk lipid phase of
themembrane via a narrow hydrophobic cavitywhich is approximately
18–20 Å long [15,27]. A surprising structural feature of this cavity is that
although the entrance is ~12 Å wide, a bottleneck formed by the pres-
ence of the L177 and L267 residues (~6 Å wide) can be detected
12–16 Å from the entrance to the cavity. Modelling studies reveal that
ubiquinol binds in a similar manner to that of the AOX inhibitors de-
scribed above namelywith its headgroupwithin 4 Å of the diiron centre
being held in position by a hydrogen bond network involving D163,
R173, E178 and S/T274 [1,15]. Given the narrowness of the cavity such
modelling studies suggest that the ubiquinol tail will be in an extended
conformation with the end of the tail (6–7 isoprenoid units) protruding
into the bulk lipid phase.
In this paper we have investigated the behaviour of several site-
speciﬁc AOX mutants in a membrane environment where AOX is ex-
posed to a natural substrate. The amino-acid residues we have identi-
ﬁed, which are suggested to play important roles in substrate and/or
inhibitor binding and are located within or close to the hydrophobic
cavity [15], include R159, D163, L177 and L267 (Fig. 1). Structural anal-
ysis reveals that D163, located on helixα1 at the entrance to the cavity,
is hydrogen bonded to R159 (helix α1) and R173 (helix α2) both of
which we have previously suggested to be important for inhibitor and
substrate-binding [1,15]. L177 and L267 are located on helices α2 and
α5 respectively and, as is apparent from Fig. 1, form the bottleneck of
the hydrophobic cavity.
We have previously demonstrated thatmutation of the T179 residue
to alanine in rSgAOX expressed in S. pombe mitochondria decreases
both the apparent Km (O2) and maximum AOX activities [34]. The
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when rSgAOX is expressed in E. coli membranes, suggesting that the
mutational effects observed are indeed a reﬂection of an alteration in
the enzyme's catalytic cycle and not due merely to alterations in mem-
brane environment or cell type. This is a particularly important point
since it not only validates the techniques used to measure such param-
eters but also means that justiﬁable comparisons can bemade between
AOXs expressed in different cell types. Indeed apparent Km (O2) for
rSgAOXmeasured in this study is similar to that reported formungbean
(12.3 μM[43]) and soybean (13.2 μM[40,44])mitochondria and equally
comparable to that observed in the recombinant system expressed in
S. pombe (20 μM [34]).
The data summarised in Table 1 suggests that those residues which
are close to the diiron centre all result in a reduction in apparent Km
(O2) when mutated. For instance the D163A, T179A and to a more lim-
ited extent L177A mutants all result in increased oxygen afﬁnities
whereas the R159 and L267 mutants remain statistically unchanged in
comparison to wild-type enzyme. This at ﬁrst may appear puzzling fol-
lowing an inspection of Fig. 1; however, it can perhaps be best explained
by the location of these residues with respect to the position of the
diirons, Fe 1 and Fe 2. Both L177 and T179 are located on helix α2 and
ﬂank E178, which co-ordinate with Fe1 [15], and both demonstrate an
apparent Km (O2) which is lower than the wild-type value. We have
previously suggested [34] that the inﬂuence of such mutations on AOX
catalysis is probably indirect and due to subtle secondary-structure
rearrangements that affect iron-ligating residues such as E178. Themu-
tation of L267, however, had little effect upon the apparent Km (O2)
even though it also ﬂanks an iron-binding ligand (E268). In this case
the iron-binding ligand is located on helix α5 and co-ordinates with
Fe2 and not with Fe1 [1]. We have previously suggested that only Fe1
is involved in the initial stages of oxygen binding during the catalytic
cycle [1,27] and hence any effect on the residues that ligate Fe1 is likely
to have a deleterious effect on AOX catalysis.
Mutagenesis of D163 andR159 to alanine substantially decreases the
maximumAOXactivities to values comparable to each other and similar
to that observed with T179. However in the case of D163 the apparent
Km (O2) is reduced considerably whilst in the R159A mutant it remains
the same as that of wild-type. As both of these residues are located on
the same helix it is initially difﬁcult to explain such a result particularly
since examination of the crystal structure reveals that R159 is closer to
the diiron core than D163 [15]. One explanation that could potentially
accommodate such results is that should the D163A mutation result in
destabilisation of the hydrogen bond formed between D163 and R173
then it may well result in a conformational change in helix α2. Such a
result is not without precedent since we have previously demonstrated
that a C172Amutation also leads to a reduction in the apparent Km (O2)
[34] even though it is also some distance from the diiron core. This
would suggest that the inﬂuence of both D163 and C172 on AOX catal-
ysis is due to indirect secondary structure re-arrangements that affect
the coordination of E178 to Fe1 and hence affect the turnover of the
catalytic cycle [27].
Data summarised in Table 2 investigated the sensitivity of bothwild-
type and mutant forms of rSgAOX to various AOX antagonists in an
attempt to determine if changes in the bottleneck of the hydrophobic
cavity resulted in any change in inhibitor sensitivity. L177 and L267 ap-
pear to form the bottleneck (Fig. 1) and hence mutation to alanine
removes the bulky isobutyl side chains thereby potentially widening
the channel whilst still retaining its hydrophobic character. The results
quite clearly demonstrated that mutation of either L177 or L267 de-
creased AOX sensitivity to all of the inhibitors tested. Importantly, how-
ever, it did dramatically increase the sensitivity to an anti-malarial
compound (PG75)whichwepreviously considered to be a poor AOX in-
hibitor (L. Young, A.L. Moore and G. Biagini, unpublished observations).
SL-2-25 and PG75 are 2-diheteroaryl quinolones which in general are
potent PfNDH2 and cytochrome Pfbc1 Qo complex inhibitors [41,42].
In contrast to AOX inhibitors such as ascofuranone or colletochlorin B,they do not possess an isoprenoid tail but a 2-heteroaryl group and
therefore lack the ﬂexibility of the isoprenoid tail. An increase in sensi-
tivity to PG75 following mutagenesis particularly of the L267 residue
suggests that themutations have indeedwidened the hydrophobic cav-
ity thereby providing access to the diiron centre by bulkier inhibitors
such as PG75. We suggest that the location of these leucine residues at
the entrance to the active-site helps to orientate both substrate and
AOX antagonists into the correct conformation to interact with the
diiron centre. Replacement with less bulky residues such as alanine
removes this ability to correctly orientate the inhibitor and thereby,
we would suggest, decreases sensitivity to AOX inhibitors. Importantly
single amino acid mutations in inhibitor/substrate pockets have been
found to be the cause of multi-drug resistant strains of malaria [41]
and the decrease in sensitivity to main AOX antagonists, observed in
the L-mutants studied in this report, suggests that an emergence of
drug resistance to trypanosomiasis may also be possible. Therefore we
suggest that the design of future AOX inhibitors should have structures
that are less reliant on the orientation by the two-leucine residues.
In conclusion we have demonstrated in this paper that mutagenesis
of a number of highly conserved residues (R159, D163, L177 and L267)
to alanine, all ofwhich line the hydrophobic inhibitor/substrate cavity in
AOX, results in a decrease in maximum activity of AOX and in some
cases (D163 and L177) a decrease in the apparent Km (O2). We have
previously suggested that such an increase in apparent O2 afﬁnity im-
plies a steady state rise of total AOX-bound oxygen [34]. This cannot re-
sult from an increase in initial O2-association alone as we would not
have observed inhibited enzyme turnover. Our datamore likely suggest
that the mutations observed in this report have altered the way in
which the enzyme's catalytic cycle is controlled, and becausemaximum
activity is decreased, they predict an increase in the steady state level of
at least one O2-derived AOX intermediate [27]. Such mutations should
therefore prove to be useful in future stopped-ﬂow and EPR experi-
ments in our attempts to understand the mechanism of oxygen
reduction and thereby facilitate the design of safer and more potent in-
hibitors for the treatment of diseases in which the AOX plays a pivotal
role such as for instance in trypanosomiasis.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbabio.2014.01.027.
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